Mylan gets tentative USFDA nod for generic of Eli Lilly lung cancer drug Alimta

Published On 2019-08-31 04:00 GMT   |   Update On 2021-08-16 09:27 GMT

Alimta is Lilly's third biggest-selling drug. The Indianapolis-based drugmaker reported second-quarter sales of $577.8 million for the medicine.


U.S: The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly & Co's lung cancer drug Alimta.


A tentative approval generally signals that the FDA has signed off on the company's marketing application, but that it cannot sell the medicine until the U.S. patents have expired.


Lilly stands to lose U.S. patent protection on the chemotherapy drug, known generically as pemetrexed, in 2022.


Read Also: Novo Nordisk files suit against Mylan to block entry of generic Victoza drug in US


Earlier this month, Lilly won a federal appeals court decision protecting its patent from copycat drugs by Pfizer Inc and India's Dr Reddy's Laboratories Ltd.


Read Also: Lawmakers push Mylan, Teva Pharma over drug pricing probe


Alimta is Lilly's third biggest-selling drug. The Indianapolis-based drugmaker reported second-quarter sales of $577.8 million for the medicine.


Read Also: Biocon, Mylan launch biosimilar Ogivri for treatment of breast, stomach cancer in Australia

Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News